ArticleThe Journal of veterinary medical science2025
Daily topical application of chlorhexidine gluconate to the skin in dogs and its impact on skin barriers and cytotoxicity.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preventive effect of bentonite against pyoderma via direct binding capability of staphylococci.PloS one · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the importance of using local disinfectants instead of systemic antibiotics for the treatment of infectious skin diseases to prevent the emergence of resistant bacteria has become widely recognized. Chlorhexidine gluconate (CHG) is commonly used in veterinary antibacterial shampoos; however, the daily topical application of diluted CHG solutions has also been adopted. Despite its widespread use, few studies have investigated the effects of CHG on the canine skin barrier. This study examined the skin barrier-damaging effects of CHG in dogs by applying diluted CHG (0.05%, 0.5%, and 4%) daily to six healthy dogs for 2 weeks. At the end of the trial, transepidermal water loss (TEWL), skin surface hydration (SSH), and number of skin bacteria were evaluated. Additionally, the cytotoxicity of CHG to the canine progenitor epidermal keratinocytes (CPEK) was examined using the water-soluble tetrazolium salt (WST-8) assay. Continuous application of 0.5% and 4% CHG to the skin led to a significant reduction in the number of skin bacteria. Additionally, at 4% CHG, a notable increase in TEWL and a decrease in SSH was observed. The WST assay revealed cytotoxicity of CHG at concentrations of 0.05%. In conclusion, although daily topical application of 4% CHG demonstrated the potential to disrupt the skin barrier, 0.5% CHG demonstrated sufficient antimicrobial activity without skin barrier disruption. Additionally, when treating dogs' skin with a compromised stratum corneum, use of lower concentration of CHG is suitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.